ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1,2,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
2,1,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2,3,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
2,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2,5,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
3,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
5,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
5,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
5,3,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
5,4,Haemodialysis,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
6,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
7,1,Intentional dose omission,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
7,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
8,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
9,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
10,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
11,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
12,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
13,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
14,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
14,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
14,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
14,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
15,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
15,2,Eye irritation,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
15,3,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
16,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
17,1,Livedo reticularis,Skin vasomotor conditions,Skin vascular abnormalities,Skin,Y
18,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
19,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
20,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
21,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
21,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
22,1,Rash morbilliform,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
23,1,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,Y
23,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
24,1,Sinus bradycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
25,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
25,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
26,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
27,1,Extravasation,General signs and symptoms NEC,General system disorders NEC,Genrl,N
28,1,Extravasation,General signs and symptoms NEC,General system disorders NEC,Genrl,N
29,1,Extravasation,General signs and symptoms NEC,General system disorders NEC,Genrl,N
30,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
31,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
32,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
33,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
34,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
35,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
36,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
36,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
36,3,Product preparation issue,Product preparation errors and issues,Medication errors and other product use errors and issues,Inj&P,N
36,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
37,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
37,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
38,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
39,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
39,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
39,3,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
40,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
41,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
42,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
43,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
44,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
44,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
44,3,Oxygen consumption increased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
44,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
45,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
46,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
46,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
47,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
48,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
49,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
50,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
51,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
51,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
52,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
53,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
53,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
53,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
54,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
54,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
54,3,Eye irritation,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
54,4,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
54,5,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
54,6,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
54,7,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
54,8,Migraine,Migraine headaches,Headaches,Nerv,N
55,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
56,1,Headache,Headaches NEC,Headaches,Nerv,N
57,1,Sinus bradycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
58,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
59,1,Renal injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
60,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
60,2,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
60,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
61,1,Renal injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
62,1,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
63,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
64,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
65,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
66,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
67,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
68,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
69,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
69,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
69,3,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
70,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
71,1,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
71,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
72,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
72,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
72,3,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
73,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
74,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
74,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
75,1,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
76,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
77,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
78,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
78,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
79,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
79,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
79,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
80,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
81,1,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
82,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
82,2,Labelled drug-drug interaction issue,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
83,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
83,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
84,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
84,2,Exposure via breast milk,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
84,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
84,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
85,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
86,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
87,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
88,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
88,2,Transaminases increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
89,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
90,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
91,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
91,2,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
91,3,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
92,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
93,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
94,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
95,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
95,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
96,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
97,1,Anuria,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
97,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
97,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
97,4,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
97,5,Respiratory depression,Breathing abnormalities,Respiratory disorders NEC,Resp,N
98,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
98,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
98,3,Sensitive skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
99,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
100,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
100,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
101,1,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
102,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
102,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
103,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
104,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
104,2,Allergic respiratory symptom,Respiratory signs and symptoms NEC,Respiratory tract signs and symptoms,Resp,N
104,3,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
104,4,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
104,5,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
104,6,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
104,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
104,8,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
104,9,Respiratory rate increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
105,1,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
106,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
106,2,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
106,3,Haemodynamic instability,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
107,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
108,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
108,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
109,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
109,2,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,N
109,3,Cerebral ventricle dilatation,Structural brain disorders NEC,Structural brain disorders,Nerv,N
109,4,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
109,5,Inflammatory marker increased,Chemistry analyses NEC,Protein and chemistry analyses NEC,Inv,N
109,6,Low birth weight baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
109,7,Neonatal respiratory distress syndrome,Neonatal hypoxic conditions,Neonatal respiratory disorders,Resp,N
109,8,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
110,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
111,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
112,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
112,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
113,1,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
114,1,Product dose omission in error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
114,2,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
115,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
116,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
117,1,Hyperamylasaemia,Metabolic disorders NEC,Metabolism disorders NEC,Metab,N
117,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
118,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
119,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
119,2,Pneumonia klebsiella,Klebsiella infections,Bacterial infectious disorders,Infec,Y
120,1,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
121,1,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
122,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
122,2,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
123,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
124,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
124,2,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
125,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
125,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
125,3,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
126,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
126,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
127,1,Hepatitis fulminant,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,Y
128,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
129,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
129,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
129,3,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
130,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
130,2,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
130,3,Meningitis bacterial,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
130,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
131,1,Salivary hypersecretion,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
131,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
132,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
132,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
133,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
133,2,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
134,1,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
134,2,Meningitis cryptococcal,Cryptococcal infections,Fungal infectious disorders,Infec,Y
134,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
134,4,Pneumonia bacterial,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
135,1,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
136,1,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,Y
136,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
136,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
136,4,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
137,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
138,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
138,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
138,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
138,4,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
139,1,Erythema nodosum,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
140,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
141,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
142,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
143,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
143,2,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
144,1,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,Y
144,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
144,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
144,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
144,5,Exophthalmos,"Structural change, deposit and degeneration of eye NEC","Ocular structural change, deposit and degeneration NEC",Eye,N
144,6,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
144,7,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
144,8,Necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
144,9,Ophthalmoplegia,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,N
144,10,Palate injury,Abdominal and gastrointestinal injuries NEC,Injuries NEC,Inj&P,N
145,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
146,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
147,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
147,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
148,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
149,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
150,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
151,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
152,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
153,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
154,1,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,Y
154,2,Secondary immunodeficiency,Acquired immunodeficiency syndromes,Immunodeficiency syndromes,Immun,N
154,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
155,1,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
156,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
157,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
158,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
159,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
160,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
161,1,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
161,2,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
161,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
